The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome

Atherosclerosis

Volumn 196, Issue 2, 2008, Pages 958-965

  Charitidou, Christina ^a   Farmakiotis, Dimitrios ^a   Zournatzi, Vassiliki ^a   Pidonia, Ifigenia ^a   Pegiou, Theodosia ^a   Karamanis, Nikolaos ^a   Hatzistilianou, Maria ^a   Katsikis, Ilias ^a   Panidis, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

ADMA; Endothelin 1; Estrogens; PCOS

Indexed keywords

ANDROGEN; ANTIANDROGEN; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DESOGESTREL PLUS ETHINYLESTRADIOL; ENDOTHELIN 1; ESTRADIOL; ESTROGEN; ESTROPAUSE; ETHINYLESTRADIOL; GLUCOSE; GONADOTROPIN; GYNOFEN 35; INSULIN; N(G),N(G) DIMETHYLARGININE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

ADULT; ANDROGEN ANTAGONISTS; ARGININE; CYPROTERONE ACETATE; DESOGESTREL; DRUG THERAPY, COMBINATION; ENDOTHELIN-1; ESTRADIOL; ESTROGENS; ESTROGENS, CONJUGATED (USP); ETHINYL ESTRADIOL; FEMALE; HORMONES; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

EID: 38349111105     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.03.002     Document Type: Article

References (39)

1. Diamanti-Kandarakis E., and Panidis D. Update on polycystic ovary syndrome. Women's Health 2 (2006) 561-569
2. 4-androstenedione levels in lean women with polycystic ovary syndrome. Fertil Steril 84 (2005) 538-540
3. Diamanti-Kandarakis E., Bartzis M.I., Zapanti E.D., et al. Polymorphism TC (-34bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 71 (1999) 431-435
4. Dunaif A., Futterweit W., Segal K.R., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
5. Nestler J.E., and Jakubowicz D.J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82 (1997) 4075-4079
6. Nestler J.E., Powers L.P., Matt D.W., et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72 (1991) 83-89
7. Dahlgren E., Janson P.O., Johansson Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based prospective population study of women. Acta Obstet Gynecol Scand 71 (1992) 599-604
8. Cussons A.J., Stuckey B.G.A., and Watts G.F. Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives. Atherosclerosis 185 (2006) 227-239
9. Macut D., Micic D., Cvijovic G., et al. Cardiovascular risk in adolescent and young adult obese females with PCOS. J Pediatr Endocrinol Metab 5 (2001) 1353-1359
10. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., and Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999) 141-146
11. Paradisi G., Steinberg H.O., Hempfling A., et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103 (2001) 1410-1415
12. Tarkun I., Arslan B.C., Canturk Z., et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89 (2004) 5592-5596
13. Kelly C.J., Speirs A., Gould G.W., et al. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 742-746
14. Diamanti-Kandarakis E., Spina G., Kouli C., and Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86 (2001) 4666-4673
15. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
16. Orio Jr. F., Palomba S., Cascella T., et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 4588-4593
17. Kravariti M., Naka K.N., Kalantaridou S.N., et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 5088-5095
18. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 339 (1992) 572-575
19. Böger R.H. The emerging role of ADMA as a novel cardiovascular risk factor. Cardiovasc Res 59 (2003) 824-833
20. Valkonen V.P., Päivä H., Salonen J.T., et al. Risk of acute coronary events and serum concentrations of asymmetric dimethylarginine. Lancet 358 (2001) 2127-2128
21. Cooke J. Assymetrical dimethylarginine. The U{combining double acute accent}ber Marker?. Circulation 109 (2004) 1813-1819
22. Böger R.H., Maas R., Schulze F., and Schwedhelm E. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 43 (2005) 1124-1129
23. Chan N.N., and Chan J.C.N. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia 45 (2002) 1609-1616
24. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome PCOS. Hum Reprod 19 (2004) 41-47
25. Diamanti-Kandarakis E., Alexandraki K., Piperi C., et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 36 (2006) 691-697
26. Kourembanas S., McQuillan L.P., and Leung G. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 92 (1993) 99-104
27. Ohnishi M., Wada A., Tsutamoto T., et al. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure. Clin Sci 103 (2002) 241S-244S
28. Cevic D., Unay O., Durmusoglu F., Yurdun T., and Bilsel A.S. Plasma markers of NO synthase activity in women after ovarian hyperstimulation: influence of estradiol on ADMA. Vasc Med 11 (2006) 7-12
29. Holden D.P., Cartwright J.E., Nussey S.S., and Whitley G. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 108 (2003) 1575-1580
30. Post M.S., Verhoeven M.O., Van der Mooren M.J., et al. Effect of hormone replacement therapy on plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early post-menopausal women. J Clin Endocrinol Metab 88 (2003) 4221-4246
31. Ishibahshi T., Obayashi S., Sakamoto S., et al. Estrogen replacement effectively improves the accelerated intimal hyperplasia following ballon injury of carotid artery in the ovariectomized rats. J Cardiovasc Pharmacol 47 (2006) 37-45
32. Holden D.P., Fickling S., Whitley G., and Nussey S.S. Plasma concentration of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obst Gynecol 178 (1998) 551-556
33. Binco J., and Majewski H. 17β-Estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS. Am J Physiol 43 (1998) H853-H859
34. Kimoto M., Whitley G.S., Tsuji H., and Ogawa T. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem (Tokyo) 117 (1995) 237-238
35. Ito A., Tsao P.S., Adimoolam S., et al. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99 (1999) 3092-3095
36. Vrbίková J., Stanická S., Dvořáková K., et al. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjuction with peroral cyproterone acetate in women with polycystic ovary syndrome. Eur J Endocrinol 150 (2004) 215-223
37. Mastorakos G., Koliopoulos C., Deligeoroglou E., Diamanti-Kandarakis E., and Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 85 (2006) 420-427
38. Kim J., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
39. Norman R.J., Davies M.J., Lord J., and Moran L. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13 (2002) 251-257